INTRODUCTION {#omx064s1}
============

Cavitary lung lesions are typically associated with bacterial or fungal infection \[[@omx064C1]\] with viral disease occurring more often in immunocompromised hosts \[[@omx064C2]\]. Other less commonly reported causes include malignancy, pulmonary embolism complicated by necrosis, cryptogenic organizing pneumonia, Langerhans' cell histiocytosis and rheumatologic disease \[[@omx064C1]\]. We recount this case of cavitary lung disease associated with active systemic lupus erythematosus (SLE) in an attempt to increase provider awareness for early recognition and management of a potentially remedial complication of SLE.

CASE DESCRIPTION {#omx064s2}
================

A 36-year-old female with SLE and class II lupus nephritis presented to the emergency room with a 5-day history of severe right-sided pleuritic chest pain that was 10/10 in intensity. Associated symptoms included fever, dyspnea and non-productive cough. Because of inadequate prior access to healthcare, she was not on any medications for her SLE. Pertinent positive of review of systems included a 2-month history of polyarthralgia and facial and upper extremity rash. Vital signs revealed a temperature of 39.1°C, blood pressure 114/61 mmHg, heart rate 102 beats per minute, respiratory rate 24 and oxygen saturation 97% at room air. Physical examination was notable for a malar rash, a raised erythematous rash over bilateral upper extremities, and right upper chest rhonchi.

Laboratory studies revealed leukocyte count 3.7 × 10^9^/L (4.3 × 10^9^--11.3 × 10^9^/L), hemoglobin 10.8 g/dL (12.0--15.3 g/dL), platelet count 145 × 10^9^/L (147 × 10^9^--409 × 10^9^/L), creatinine 2.37 g/dL compared to her baseline creatinine 1.00 g/dL (0.550--1.02 g/dL), blood urea nitrogen 35 mg/dL (7--18 mg/dL), albumin 2.5 g/dL (3.4--5.0 g/dL) and total protein 8.5 g/dL (6.4--8.2 g/dL). The remaining electrolytes and liver enzymes were normal. Thyroid-stimulating hormone level was 1.91 mlU/L (0.358--3.740 mlU/L) but erythrocyte sedimentation rate and C-reactive protein were more than 120 mm/h (0--20 mm/h) and 30.6 mg/dL (0.00--0.30 mg/dL), respectively. Chest x-ray (CXR) revealed a right upper lobe opacity and pleural effusion (Fig. [1](#omx064F1){ref-type="fig"}) that was confirmed on computed tomography with angiography of the chest as a new 5-cm cavitary lesion in the right hilum without evidence of pulmonary embolism (Fig. [2](#omx064F2){ref-type="fig"}). Review of medical records indicated that the patient presented to her primary care provider 1 month prior to her admission with a 2-week history of non-productive cough, for which a CT chest was done but was without cavitary lesion (Fig. [3](#omx064F3){ref-type="fig"}). Inpatient, she was started on vancomycin, piperacillin/tazobactam, levofloxacin and fluconazole. Infectious workup was negative, including blood and sputum cultures, and serum screening for cytomegalovirus, coccidioides, cryptococcus, histoplasma and aspergillus. Quantiferon-TB Gold result was indeterminate but subsequent acid-fast sputum culture was negative. Cytology of bronchoalveolar lavage and pleural fluid from thoracentesis were also negative. Despite negative infectious evaluation and antibiotics, pleuritic chest pain and intermittent fever persisted.

![Chest x-ray showed right upper lobe opacity and pleural effusion.](omx064f01){#omx064F1}

![CT angiography of the chest performed at the time of admission showing a 5-cm cavitary lesion in the right hilum.](omx064f02){#omx064F2}

![CT chest with and without contrast performed 1 month prior to hospitalization.](omx064f03){#omx064F3}

Relative to her known diagnosis of SLE, dsDNA-, Smith- and RNP-antibody were positive and ANA titer was 1:640 with speckled pattern. Serum complement C3 and C4 levels were decreased in addition to nephrotic-range proteinuria, implicating active SLE. Due to concern for progression of SLE-induced renal disease, a kidney biopsy was done and yielded a diagnosis of class IV lupus nephritis. In agreement with rheumatology, infectious disease and pulmonary care consultants, the patient was given intravenous methylprednisolone 500 mg daily for three days followed by 1 mg/kg/day. Of note, at the time when corticosteroids were started, the patient was solely on antibiotic therapy for 10 days without clinical or laboratory evidence of improvement. The patient quickly responded to corticosteroids with resolution of pleuritis, rash and polyarthralgia. She remained afebrile with substantial improvement of right upper lobe opacity and pleural effusion on follow-up CXR (Fig. [4](#omx064F4){ref-type="fig"}). Antibiotics were de-escalated, and, at the time of discharge, the patient was switched to oral prednisone in addition to continuing hydroxychloroquine and mycophenolate mofetil. Repeat chest CT 16 weeks after her hospitalization revealed complete resolution of the lesion without evidence of recurrence or complications such as pneumothorax or pulmonary fibrosis (Fig. [5](#omx064F5){ref-type="fig"}) also with normalized serum creatinine.

![Repeat chest x-ray prior to discharge showing improvement of right upper lobe opacity.](omx064f04){#omx064F4}

![Repeat CT chest 16 weeks after discharge showing resolution of the cavitary lesion.](omx064f05){#omx064F5}

DISCUSSION {#omx064s3}
==========

As previously mentioned, cavitary lung lesions are typically associated with bacterial, fungal and viral infections \[[@omx064C1], [@omx064C2]\]. While pulmonary manifestations of rheumatologic diseases are variable \[[@omx064C3]\], with the exception of granulomatosus with polyangiitis (GPA), cavitary lesions are not typical \[[@omx064C1]\]. The frequency in GPA ranges from 16 to 50% on CT imaging \[[@omx064C1]\]. Other less common autoimmune diseases that are associated with cavitary lung lesions include sarcoidosis and ankylosing spondylitis \[[@omx064C1]\]. Pulmonary manifestations of SLE may include pneumonia, interstitial pneumonitis, atelectasis, pulmonary edema, pulmonary hypertension and diffuse alveolar hemorrhage \[[@omx064C4]\].

As evidenced by a detailed review of the literature, the association between SLE and cavitary lung lesions is rare and its pathogenesis has yet to be established. The vast majority of the reported cases of SLE-related cavitary lung lesions were due to cytomegalovirus infection \[[@omx064C2]\], bacterial/fungal infections, vasculitis or as a result of necrotic infarction \[[@omx064C4]\]. Torok *et al.* \[[@omx064C5]\] reported a case of a pulmonary cavitary lesion in a patient who was newly diagnosed with SLE when he presented with the cavitary lung lesion. Lung biopsy was performed with pathology finding of venous thrombosis. The patient's condition improved with 3 months of prednisone and low molecular weight heparin. In addition, the authors provided a comprehensive review of reported cases of pulmonary cavitary lesion associated with SLE \[[@omx064C5]\]. Consistent with our review, majority of the cases were infectious in origin. Furthermore, none of the reported cases provided insight into the time to development of a cavitary lung lesion. With the availability of normal CT chest 1 month prior to her hospitalization and the appearance of cavitation within 1 month implicates a rapid course of disease progression in SLE.

The case reported by Dalili *et al.* \[[@omx064C6]\] share similar characteristics with our case. Both patients are young with a history of SLE complicated by lupus nephritis in which they presented with fever, non-productive cough, malar rash and polyarthralgia. Poor response to antibiotic therapy was demonstrated in both cases. While our case responded well to methylprednisolone, the previously reported patient briefly responded to intravenous methylprednisolone before succumbing to cardiopulmonary distress from pneumothorax.

In managing patients with pulmonary complications due to active SLE, systemic steroids are the gold standard treatment. However, it is essential to rule out infection prior to starting systemic steroids as it bears the risk of further compromising the patient's immune system. In our patient, we initiated treatment for active SLE after a negative extensive infectious workup. Given the nature of the disease process, unremarkable chest CT 1 month prior to hospitalization, and discussion with pulmonary and infectious disease providers, we opted to proceed with steroid therapy. This further demonstrates the importance of multidisciplinary collaboration.

While SLE-induced cavitary lesions are certainly responsive to corticosteroid, clinicians must be mindful of the balance between preventing infection while still providing adequate immunosuppression. Ongoing monitoring of clinical and laboratory markers is important not only to allow early capturing of superimposed infection due to the immunosuppressant effect of corticosteroid, but also to prevent recurrence and the arising of other pulmonary manifestations. Given that none of the previously recorded cases provided information on follow-up condition of their patients (due to death in a few cases), the exact duration of the monitoring effort is not clear. As in our patient, a follow-up with repeat CT chest 4 months after her discharge from the hospital showed resolution of the cavitary lesion without evidence of recurrence or active infection. Further multidisciplinary collaboration between the patient's primary care physician with rheumatology and pulmonology is essential to providing quality care to complex patient populations as well as to monitor any other pulmonary manifestations relating to rheumatologic conditions in general.

Our case underscores the importance of including SLE in the differential diagnosis of cavitary lung disease and we encourage further reports and research of the same.
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